INTERVIEW: BD On China-Appropriate Growth Strategy
This article was originally published in PharmAsia News
Becton Dickinson has been growing north of 20% several years in a row in China, which has now overtaken Japan to become the U.S. firm’s second largest market. Local needs-based product customization and innovation, and commercial partnerships with national players win the day, says Becton Dickinson China general manager James Deng in an exclusive interview.
You may also be interested in...
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.
One year after the first cases of a novel coronavirus emerged in Wuhan, a team from the World Health Organization has arrived in the city to investigate its origin. Meanwhile, mixed results are reported for some of the leading Chinese vaccines being developed to fight the pandemic still wreaking global havoc.
China's innovative drug makers step into the spotlight by grabbing green lights for cancer drugs in the country's latest batch of product approvals.